These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 28475378)

  • 1. Clinical development of biologicals and biosimilars - safety concerns.
    Bonovas S; Peyrin-Biroulet L; Danese S
    Expert Rev Clin Pharmacol; 2017 Jun; 10(6):567-569. PubMed ID: 28475378
    [No Abstract]   [Full Text] [Related]  

  • 2. Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence.
    McConachie S; Wilhelm SM; Kale-Pradhan PB
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):391-400. PubMed ID: 28095262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars: Implications for health-system pharmacists.
    Lucio SD; Stevenson JG; Hoffman JM
    Am J Health Syst Pharm; 2013 Nov; 70(22):2004-17. PubMed ID: 24173009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
    Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
    Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biosimilars in inflammatory bowel disease].
    Siegmund B; Atreya R; Bokemeyer B; Kruis W; Mudter J; Sander C; Schreiber S; Reindl W; Zeissig S; Kucharzik T
    Z Gastroenterol; 2016 Nov; 54(11):1217-1222. PubMed ID: 27711946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis.
    Reynolds KA; Pithadia DJ; Lee EB; Liao W; Wu JJ
    Am J Clin Dermatol; 2020 Aug; 21(4):483-491. PubMed ID: 32048187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA Biosimilar Action Plan: could improving pharmacovigilance of biologics improve patient and physician confidence in biosimilars?
    Jordan JB; Christl L
    Expert Opin Drug Saf; 2020 Mar; 19(3):229-232. PubMed ID: 32098520
    [No Abstract]   [Full Text] [Related]  

  • 8. Biosimilars in oncology: everybody agrees but nobody uses?
    Gyawali B
    Recenti Prog Med; 2017 Apr; 108(4):172-174. PubMed ID: 28492585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing safety information of biosimilars with their originators: a cross-sectional analysis of European risk management plans.
    Lepelaars LRA; Renda F; Pani L; Pimpinella G; Leufkens HGM; Trifirò G; Tafuri G; Mantel-Teeuwisse AK; Trotta F
    Br J Clin Pharmacol; 2018 Apr; 84(4):738-763. PubMed ID: 29164665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies? A review.
    Reynolds KA; Pithadia DJ; Lee EB; Han G; Wu JJ
    Expert Opin Drug Saf; 2020 Apr; 19(4):459-466. PubMed ID: 32116071
    [No Abstract]   [Full Text] [Related]  

  • 11. How Similar are Biosimilars? Time to Switch a Position.
    Houri Levi E; Amital H
    Isr Med Assoc J; 2021 Jun; 23(6):376-377. PubMed ID: 34155852
    [No Abstract]   [Full Text] [Related]  

  • 12. Biosimilars.
    Bagel J
    J Drugs Dermatol; 2014 Jul; 13(7):788-90. PubMed ID: 25007360
    [No Abstract]   [Full Text] [Related]  

  • 13. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
    Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Considerations related to comparative clinical studies for biosimilars.
    Rathore AS; Stevenson JG; Chhabra H
    Expert Opin Drug Saf; 2021 Mar; 20(3):265-274. PubMed ID: 33455482
    [No Abstract]   [Full Text] [Related]  

  • 15. Assays used to assess biosimilarity of therapies for inflammatory bowel disease.
    Veisman I; Ben-Horin S
    Expert Opin Drug Discov; 2020 Feb; 15(2):139-144. PubMed ID: 31805797
    [No Abstract]   [Full Text] [Related]  

  • 16. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologicals and biosimilars: safety issues in Europe.
    Portela MDCC; Sinogas C; Albuquerque de Almeida F; Baptista-Leite R; Castro-Caldas A
    Expert Opin Biol Ther; 2017 Jul; 17(7):871-877. PubMed ID: 28540760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacovigilance of Biologics in a Multisource Environment.
    Sagi S; Cohen HP; Woollett GR
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1249-1254. PubMed ID: 29172979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars in inflammatory bowel disease.
    Gargallo CJ; Lué A; Gomollón F
    Minerva Med; 2017 Jun; 108(3):239-254. PubMed ID: 28176515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters.
    Kim H; Alten R; Cummings F; Danese S; D'Haens G; Emery P; Ghosh S; Gilletta de Saint Joseph C; Lee J; Lindsay JO; Nikiphorou E; Parker B; Schreiber S; Simoens S; Westhovens R; Jeong JH; Peyrin-Biroulet L
    MAbs; 2021; 13(1):1868078. PubMed ID: 33557682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.